Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CollaGenex Pharmaceuticals, Inc.
CollaGenex Pharmaceuticals Announces Expiration of the Hart-Scott-Rodino Waiting Period for Merger with Galderma Pharma S.A.
April 5th, 2008
CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the pending merger of CollaGenex with an affiliate of Galderma Pharma S.A.. As previously announced, the merger has been structured as a two-step transaction involving a cash tender offer for all outstanding shares of CollaGenex common stock followed by a cash merger in which Galderma would acquire any remaining shares of CollaGenex common stock. Galderma, through a wholly owned subsidiary, commenced the cash tender offer on March 7, 2008, to purchase all of the outstanding shares of...
Source: Law & Health Weekly (2008-04-05)
|
